Decreased CaMKII and PKC activities in specific brain regions are associated with cognitive impairment in neonatal ventral hippocampus-lesioned rats

Neuroscience

Volumn 234, Issue , 2013, Pages 103-115

  Yabuki, Y ^a   Nakagawasai, O ^b   Moriguchi, S ^a   Shioda, N ^a   Onogi, H ^b   Tan No, K ^b   Tadano, T ^b   Fukunaga, K ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Ca2+ calmodulin dependent protein kinase II; Cognitive dysfunction; Dopamine and cAMP regulated phosphoprotein 32; NMDA receptor; NVH lesioned rats; Schizophrenia

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; GLUTAMATE RECEPTOR 1; PHOSPHOPROTEIN DARPP 32; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; RISPERIDONE; SERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; BRAIN DAMAGE; BRAIN REGION; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; HIPPOCAMPAL CA1 REGION; IMMUNOHISTOCHEMISTRY; MALE; NEONATAL VENTRAL HIPPOCAMPUS LESION; NEUROCHEMISTRY; NEWBORN; NONHUMAN; PHENOTYPE; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

ANIMALS; ANIMALS, NEWBORN; ANTIPSYCHOTIC AGENTS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; COGNITION DISORDERS; CORPUS STRIATUM; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; HIPPOCAMPUS; LONG-TERM POTENTIATION; MALE; NEURAL INHIBITION; PHOSPHORYLATION; PREFRONTAL CORTEX; PROTEIN KINASE C-ALPHA; RATS; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; RISPERIDONE;

EID: 84873517367     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.12.048     Document Type: Article

References (60)

1. Addington J., Addington D., Gasbarre L. Neurocognitive and social functioning in schizophrenia and other diagnoses. Schizophr Res 2001, 48:367-368.
2. Al-Khairi I., Baharnoori M., Kamath A., Bhardwaj S.K., Srivastava L.K. Altered expression and alpha-1 adrenergic receptor mediated activity of protein kinase C in the prefrontal cortex of rats with neonatal ventral hippocampus lesions. Synapse 2009, 63:1051-1059.
3. Alquicer G., Silva-Gomez A.B., Peralta F., Flores G. Neonatal ventral hippocampus lesion alters the dopamine content in the limbic regions in postpubertal rats. Int J Dev Neurosci 2004, 22:103-111.
4. Alkon D.L., Sun M.K., Nelson T.J. PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease. Trends Pharmacol Sci 2007, 28:51-60.
5. Ban T.A., Guy W., Wilson W.H. Description and distribution of the subtypes of chronic schizophrenia based on Leonhard's classification. Psychiatr Dev 1984, 2:179-199.
6. Bhardwaj S.K., Quirion R., Srivastava L.K. Post-pubertal adrenergic changes in rats with neonatal lesions of the ventral hippocampus. Neuropharmacology 2004, 46:85-94.
7. Chambers R.A., Moore J., McEvoy J.P., Levin E.D. Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. Neuropsychopharmacology 1996, 15:587-594.
8. Collingridge G.L., Isaac J.T., Wang Y.T. Receptor trafficking and synaptic plasticity. Nat Rev Neurosci 2004, 5:952-962.
9. Conklin H.M., Curtis C.E., Calkins M.E., Iacono W.G. Working memory functioning in schizophrenia patients and their first degree relatives: cognitive functioning shedding light on etiology. Neuropsychologia 2005, 43:930-942.
10. Cuesta M.J., Peralta V., Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res 2001, 48:17-28.
11. Eijkenboom M., Blokland A., Van Der Staay F.J. Modeling cognitive dysfunction with bilateral injection of ibotenic acid into the rat entorhinal cortex. Neuroscience 2000, 101:27-39.
12. Flores G., Alquicer G., Silva-Gómez A.B., Zaldivar G., Stewart J., Quirion R., Srivastava L.K. Alterations in dendritic morphology of prefrontal cortical and nucleus accumbens neurons in post-pubertal rats after neonatal excitotoxic lesions of the ventral hippocampus. Neuroscience 2005, 133:463-470.
13. Flores G., Barbeau D., Quirion R., Srivastava L.K. Decreased binding of dopamine D3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus. J Neurosci 1996, 16:2020-2026.
14. Fukunaga K., Shioda N., Miyamoto E. The function of CaM kinase II in synaptic plasticity and spine formation. Handbook of neurochemistry and molecular neurobiology. Neural signaling mechanisms 2009, 163-183. Springer, New York. A. Lajtha (Ed.).
15. Fukunaga K., Goto S., Miyamoto E. Immunohistochemical localization of Ca2+/calmodulin-dependent protein kinase II in rat brain and various tissues. J Neurochem 1988, 51:1070-1078.
16. Giese K.P., Fedorov N.B., Filipkowski R.K., Silva A.J. Autophosphorylation at Thr286 of the alpha calcium-calmodulin kinase II in LTP and learning. Science 1998, 279:870-873.
17. Grayson B., Idris N.F., Neill J.C. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res 2007, 184:31-38.
18. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 1996, 153:321-330.
19. Hertel P., Nomikos G.G., Iurlo M., Svensson T.H. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology (Berl) 1996, 124:74-86.
20. Jay T.M. Dopamine: a potential substrate for synaptic plasticity and memory mechanisms. Prog Neurobiol 2003, 69:375-390.
21. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20:201-225.
22. Kamphuis W., Hendriksen E., Lopes da Silva F.H. Isozyme specific changes in the expression of protein kinase C isozyme (alpha-zeta) genes in the hippocampus of rats induced by kindling epileptogenesis. Brain Res 1995, 702:94-100.
23. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003, 160:13-23.
24. Kato K., Shishido T., Ono M., Shishido K., Kobayashi M., Niwa S. Glycine reduces novelty- and methamphetamine induced locomotor activity in neonatal ventral hippocampal damaged rats. Neuropsychopharmacology 2001, 24:330-332.
25. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007, 64:633-647.
26. Kitajima I., Yamamoto T., Ohno M., Ueki S. Working and reference memory in rats in the three-panel runway task following dorsal hippocampal lesions. Jpn J Pharmacol 1992, 58:175-183.
27. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51:199-214.
28. Laplante F., Nakagawasai O., Srivastava L.K., Quirion R. Alterations in behavioral responses to a cholinergic agonist in post-pubertal rats with neonatal ventral hippocampal lesions: relationship to changes in muscarinic receptor levels. Neuropsychopharmacology 2005, 30:1076-1087.
29. Le Pen G., Gaudet L., Mortas P., Mory R., Moreau J.L. Deficits in reward sensitivity in a neurodevelopmental rat model of schizophrenia. Psychopharmacology (Berl) 2002, 161:434-441.
30. Le Pen G., Moreau J.L. Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol. Neuropsychopharmacology 2002, 27:1-11.
31. Le Pen G., Kew J., Alberati D., Borroni E., Heitz M.P., Moreau J.L. Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor. Biol Psychiatry 2003, 54:1162-1170.
32. Li Z., Huang M., Prus A.J., Dai J., Meltzer H.Y. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus. Brain Res 2007, 1134:70-78.
33. Lipska B.K., Aultman J.M., Verma A., Weinberger D.R., Moghaddam B. Neonatal damage of the ventral hippocampus impairs working memory in the rat. Neuropsychopharmacology 2002, 27:47-54.
34. Lipska B.K., Jaskiw G.E., Weinberger D.R. Postpubertal emergence of hyper-responsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 1993, 9:67-75.
35. Lipska B.K., Swerdlow N.R., Geyer M.A., Jaskiw G.E., Braff D.L., Weinberger D.R. Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology (Berl) 1995, 122:35-43.
36. Lipska B.K., Weinberger D.R. Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage. Neuropsychopharmacology 1994, 10:199-205.
37. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., Grace A.A. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008, 31:234-242.
38. Lisman J., Schulman H., Cline H. The molecular basis of CaMKII function in synaptic and behavioural memory. Nat Rev Neurosci 2002, 3:175-190.
39. Marcotte E.R., Pearson D.M., Srivastava L.K. Animal models of schizophrenia: a critical review. J Psychiatry Neurosci 2001, 26:395-410.
40. Masri B., Salahpour A., Didriksen M., Ghisi V., Beaulieu J.M., Gainetdinov R.R., Caron M.G. Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A 2008, 105:13656-13661.
41. McIlwain K.L., Merriweather M.Y., Yuva-Paylor L.A., Paylor R. The use of behavioral test batteries: effects of training history. Physiol Behav 2001, 73:705-717.
42. McLean S.L., Neill J.C., Idris N.F., Marston H.M., Wong E.H., Shahid M. Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat. Behav Brain Res 2010, 214:240-247.
43. Meltzer H.Y., McGurk S.R. The effect of clozapine, resperidone and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999, 25:233-255.
44. Meyer-Lindenberg A., Miletich R.S., Kohn P.D., Esposito G., Carson R.E., Quarantelli M., Weinberger D.R., Berman K.F. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002, 5:267-271.
45. Mouri A., Noda Y., Noda A., Nakamura T., Tokura T., Yura Y., Nitta A., Furukawa H., Nabeshima T. Involvement of a dysfunctional dopamine-D1/N-methyl-d-aspartate-NR1 and Ca2+/calmodulin-dependent protein kinase II pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine. Mol Pharmacol 2007, 71:1598-1609.
46. Murai R., Noda Y., Matsui K., Kamei H., Mouri A., Matsuba K., Nitta A., Furukawa H., Nabeshima T. Hypofunctional glutamatergic neurotransmission in the prefrontal cortex is involved in the emotional deficit induced by repeated treatment with phencyclidine in mice: implications for abnormalities of glutamate release and NMDA-CaMKII signaling. Behav Brain Res 2007, 180:152-160.
47. Nakagawasai O., Hozumi S., Tan-No K., Niijima F., Arai Y., Yasuhara H., Tadano T. Immunohistochemical fluorescence intensity reduction of brain somatostatin in the impairment of learning and memory-related behaviour induced by olfactory bulbectomy. Behav Brain Res 2003, 142:63-67.
48. Onogi H., Nakagawasai O., Tan-No K., Mitazaki S., Sato A., Nakaya K., Niijima F., Arai Y., Kikuchi T., Tadano T. p-Hydroxyamphetamine causes prepulse inhibition disruptions in mice: contribution of dopamine neurotransmission. Behav Brain Res 2010, 214:349-356.
49. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, New York. 4th ed.
50. Qiao H., Noda Y., Kamei H., Nagai T., Furukawa H., Miura H., Kayukawa Y., Ohta T., Nabeshima T. Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport 2001, 12:11-15.
51. Rueter L.E., Ballard M.E., Gallagher K.B., Basso A.M., Curzon P., Kohlhaas K.L. Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia. Psychopharmacology (Berl) 2004, 176:312-319.
52. Sams-Dodd F., Lipska B.K., Weinberger D.R. Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology (Berl) 1997, 132:303-310.
53. Sanchez-Perez A.M., Felipo V. Serines 890 and 896 of the NMDA receptor subunit NR1 are differentially phosphorylated by protein kinase C isoforms. Neurochem Int 2005, 47:84-91.
54. Schroeder H., Grecksch G., Becker A., Bogerts B., Hoellt V. Alterations of the dopaminergic and glutamatergic neurotransmission in adult rats with postnatal ibotenic acid hippocampal lesion. Psychopharmacology 1999, 145:61-66.
55. Steinpreis R.E. The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis. Behav Brain Res 1996, 74:45-55.
56. Sutoo D., Akiyama K., Yabe K. Comparison analysis of distributions of tyrosine hydroxylase, calmodulin and calcium/calmodulin-dependent protein kinase II in a triple stained slice of rat brain. Brain Res 2002, 933:1-11.
57. Svenningsson P., Tzavara E.T., Carruthers R., Rachleff I., Wattler S., Nehls M., McKinzie D.L., Fienberg A.A., Nomikos G.G., Greengard P. Diverse psychotomimetics act through a common signaling pathway. Science 2003, 302:1412-1415.
58. Walaas S.I., Aswad D.W., Greengard P. A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions. Nature 1983, 301:69-71.
59. Westerink B.H., Kawahara Y., De Boer P., Geels C., De Vries J.B., Wikström H.V., Van Kalkeren A., Van Vliet B., Kruse C.G., Long S.K. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur J Pharmacol 2001, 412:127-138.
60. Williams G.V., Goldman-Rakic P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995, 376:572-575.